JBIO · XBRL financial data

Jade Biosciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (JBIO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	14,987	38,622	64,219	53,187	93,121
General and administrative	8,035	14,615	17,190	21,409	20,421
Total operating expenses	23,022	53,237	81,409	74,596	113,542
Operating income (loss)	(23,022)	(53,237)	(81,409)	(74,596)	(113,542)
Other income (expense)	62	1,751	5,944	(19)	(8)
Income tax expense (benefit)	3	25	56	55	58
Net income (loss)	(22,963)	(51,511)	(75,521)	(69,628)	(127,410)
Earnings per share, basic USD per share	(1.87)	(2.10)	(2.87)	(2.44)	(3.19)
Earnings per share, diluted USD per share	(1.87)	(2.10)	(2.87)	(2.44)	(3.19)
Weighted average shares, basic thousands of shares	12,294	24,472	26,332	28,582	31,360
Weighted average shares, diluted thousands of shares	12,294	24,472	26,332	28,582	31,360

Fiscal years (JBIO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	54,197	22,397	23,491	33,751	88,438
Short-term investments	113,178	106,823	98,948	44,872	247,720
Prepaid and other current assets	6,958	2,276	1,793	1,494	12,658
Total current assets	174,333	131,496	124,232	80,117	348,816
Property and equipment, net	186	242	288	6	170
Right-of-use asset	542	1,003	614	209	726
Total assets	175,363	135,301	127,418	80,332	349,781
Accounts payable	1,208	2,575	2,396	224	2,151
Accrued liabilities	—	—	—	4,125	9,419
Total current liabilities	2,550	7,782	17,637	3,828	16,539
Lease liability, non-current	382	705	255	0	724
Total liabilities	2,945	8,558	17,962	3,898	17,263
Accumulated deficit	(36,392)	(87,903)	(163,424)	(233,052)	(174,389)
Total stockholders' equity	172,418	126,743	109,456	76,434	332,518
Total liabilities and equity	175,363	135,301	127,418	80,332	349,781
Common shares outstanding (cover page) thousands of shares	24,410	24,812	27,863	28,985	49,316

Fiscal years (JBIO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,963)	(51,511)	(75,521)	(69,628)	(127,410)
Stock-based compensation	2,043	5,476	11,906	11,311	20,009
Net cash from operating activities	(27,399)	(39,122)	(56,778)	(71,196)	(94,689)
Purchases of property and equipment	181	195	142	—	196
Net cash from investing activities	(113,434)	6,926	11,876	56,029	(247,006)
Proceeds from issuing common stock	126,945	—	44,888	23,942	—
Net cash from financing activities	190,457	396	45,996	25,427	360,768
Net change in cash	49,624	(31,800)	1,094	10,260	19,052

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Jade Biosciences	107,250	not reported	(43,656)*	63.6M	10.6 quarters	Q2 FY26 10-QJun 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Ocugen	24,632	1,951	(15,739)*	339.3M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39,267	10,131	(75,770)*	34.1M	13.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 7:30 PM ET. The filing on SEC.gov is the record.